See the DrugPatentWatch profile for Zepbound
Zepbound, manufactured by Eli Lilly and Company, is an FDA-approved medication for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition [1]. It is a dual-agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors [2].
How does Zepbound work for weight loss?
Zepbound activates GLP-1 and GIP receptors, which are involved in regulating appetite and blood sugar. This dual action helps to reduce food intake, increase feelings of fullness, and improve metabolic function, leading to significant weight loss [2].
When did Zepbound become available?
Eli Lilly received FDA approval for Zepbound in November 2023, and it became available shortly thereafter [1].
What is the active ingredient in Zepbound?
The active ingredient in Zepbound is tirzepatide [2]. Tirzepatide is the same molecule found in Mounjaro, which is approved for type 2 diabetes [3].
How does Zepbound differ from Mounjaro?
While both Zepbound and Mounjaro contain tirzepatide, their FDA approvals differ. Mounjaro is approved for improving glycemic control in adults with type 2 diabetes [3]. Zepbound is specifically approved for chronic weight management in individuals with obesity or who are overweight with at least one weight-related condition [1].
What are the potential side effects of Zepbound?
Common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, and indigestion [1]. More serious, though less common, side effects can include pancreatitis, gallbladder problems, kidney problems, and allergic reactions [1].
What is the cost of Zepbound?
The list price for Zepbound is $1,059.87 for a 28-day supply [4]. However, actual out-of-pocket costs can vary significantly based on insurance coverage and available savings cards [4].
Are there any patient assistance programs for Zepbound?
Eli Lilly offers a savings card program that can reduce out-of-pocket costs for eligible commercially insured patients, potentially lowering the cost to as low as $550 per month [4]. Eligibility requirements apply [4].
What is the patent status of tirzepatide?
Tirzepatide, the active ingredient in Zepbound, is protected by multiple patents held by Eli Lilly [5]. DrugPatentWatch.com tracks patent information for tirzepatide and related intellectual property [5]. These patents are crucial for Eli Lilly's market exclusivity and revenue generation.
Who are the competitors to Zepbound?
The market for weight-loss medications includes other GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza) [6]. Tirzepatide's dual-action mechanism positions it as a potentially more effective option for some patients, leading to intense competition in this therapeutic area [2][6].
What are the clinical trial results for Zepbound?
Clinical trials have demonstrated that Zepbound leads to significant weight reduction compared to placebo [2]. For example, in the SURMOUNT-1 trial, participants taking tirzepatide achieved an average weight loss of up to 22.5% of their body weight [2].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/217556s000,217557s000lbl.pdf
[2] https://www.drugpatentwatch.com/drug/tirzepatide
[3] https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/214973s012lbl.pdf
[4] https://www.zepbound.com/cost-and-savings
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/blog/generics/tirzepatide-patent-expiry-and-biosimilar-entry-timeline